JHancock Classic Value R2 holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
John Hancock Classic Value Fund Class R2 JCVSX
- NAV / 1-Day Return 21.51 / −0.42 %
- Total Assets 531.0M
-
Adj. Expense Ratio
1.250%
- Expense Ratio 1.270%
- Distribution Fee Level Average
- Share Class Type Retirement, Medium
- Category Mid-Cap Value
- Investment Style Mid Value
- Min. Initial Investment 0
- Status Open
- TTM Yield 1.65%
- Turnover 13%
USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 12:11 AM GMT+0
Morningstar’s Analysis JCVSX
Will JCVSX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 40.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Humana Inc | 6.42 | 34M | Healthcare |
Baxter International Inc | 4.83 | 26M | Healthcare |
Usd | 4.78 | 25M | Cash and Equivalents |
Skyworks Solutions Inc | 4.48 | 24M | Technology |
CVS Health Corp | 4.24 | 22M | Healthcare |
Fresenius Medical Care AG ADR | 3.57 | 19M | Healthcare |
MetLife Inc | 3.40 | 18M | Financial Services |
Magna International Inc | 3.39 | 18M | Consumer Cyclical |
Lear Corp | 3.36 | 18M | Consumer Cyclical |
Cognizant Technology Solutions Corp Class A | 3.31 | 17M | Technology |